Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chinese Contaminant Was Inexpensive Heparin Mimic – U.S. FDA

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA has identified the contaminant found in heparin linked to hundreds of adverse events as synthetically altered over-sulfated chondroitin sulfate, the agency announced during a March 19 conference call

You may also be interested in...



U.S. FDA Launches First Overseas Office in Beijing

U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress

FDA Launches First Overseas Office In Beijing

Eight FDA staffers in three offices face language, volume challenges watchdogging 500 plus Chinese firms exporting drug components to the U.S.

U.S. FDA Launches First Overseas Office in Beijing

U.S. HHS Secretary Michael Leavitt and U.S. FDA Commissioner Andrew von Eschenbach officially opened the first overseas FDA office Nov. 19 in Beijing in a continuing effort to improve foreign product safety, while the agency faces criticism from the U.S. Congress

Related Content

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel